1. Marigowda G, Liu F, Waltz D. Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy. J Cyst Fibros 2016. 2. Labaste A, Ohlmann C, Mainguy C, Jubin V, Perceval M et al. Real-life acute lung function changes after lumacaftor/ivacaftor first administration in paediatric patients with cystic fibrosis.
were compared to the 62 with successful testing. Infants were divided into two groups based on gestation, 38 weeks and below and 39 weeks and above. Results were dichotomised into sufficient and insufficient (QNS) results. The Chi square test indicated that there is a statistically significant association between gestational age and sufficient or insufficient result. (p=0.004) Discussion It would be helpful to compare our data to the same cohort in other centres and national rate to see if this is an acceptable QNS rate and obtain further data regarding gestational age. Collection techniques and laboratory analysis have already been optimised with current equipment and staff. Consideration could be given to delay offering sweat test by one to two weeks to those born at 37 and 38 weeks gestation in infants who only have 1 mutation. This may reduce need for time consuming and stressful repeat testing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.